View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 29, 2019updated 09 Aug 2019 3:10pm

Kodiak’s anti-VEGF antibody yields positive data in Phase Ib study

Kodiak Sciences has reported positive interim findings from an ongoing Phase Ib clinical trial of its anti-VEGF antibody biopolymer conjugate, KSI-301, for the treatment of three eye disorders.

Kodiak Sciences has reported positive interim findings from an ongoing Phase Ib clinical trial of its anti-VEGF antibody biopolymer conjugate, KSI-301, for the treatment of three eye disorders.

KSI-301 is an investigational product intended to provide first-line therapy for retinal vascular diseases. It has been formulated for intravitreal administration.

In the Phase Ib study, the company enrolled patients with wet age-related macular degeneration (AMD), diabetic macular oedema (DME), and macular oedema caused by retinal vein occlusion (RVO).

Participants received three monthly doses of 2.5mg or 5mg KSI-301 and were monitored for the following seven months. They also had additional treatments based on protocol-specified criteria.

Data from 35 patients showed improvements in vision and retinal anatomy over 12 weeks.

Kodiak said that vision was measured as the change in best-corrected visual acuity (BCVA) on a standardised eye chart, with retinal anatomy measurement being the change in retinal central subfield thickness (CST).

As of the data cut-off date, the Phase Ib trial recruited 77 patients who were exposed to multiple doses of KSI-301. The therapeutic was well-tolerated, without any drug-related adverse events or serious adverse events.

According to the results, most of the adverse events observed during the study were mild and consistent with those associated with intravitreally-injected anti-VEGF agents.

Based on these positive findings, the company is planning to expand the study with additional cohorts.

Kodiak Sciences chief medical officer and chief development officer Jason Ehrlich said: “In addition to vision and anatomic improvements, we have observed encouraging signs of disease modification. These findings increase our conviction in the promise of KSI-301 and the further potential of our ABC Platform.”

The company intends to start patient enrolment in a head-to-head Phase II trial of KSI-301 for treatment-naïve wet AMD patients in the third quarter of this year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena